Your browser is no longer supported. Please, upgrade your browser.
Settings
KIN Kindred Biosciences, Inc. daily Stock Chart
KIN [NASD]
Kindred Biosciences, Inc.
Index- P/E- EPS (ttm)-1.64 Insider Own5.87% Shs Outstand38.50M Perf Week-1.94%
Market Cap292.60M Forward P/E- EPS next Y-1.32 Insider Trans0.00% Shs Float36.81M Perf Month-14.03%
Income-61.10M PEG- EPS next Q-0.37 Inst Own68.00% Short Float1.88% Perf Quarter7.34%
Sales4.20M P/S69.67 EPS this Y-30.20% Inst Trans-0.01% Short Ratio6.33 Perf Half Y-5.12%
Book/sh2.45 P/B3.10 EPS next Y14.30% ROA-50.70% Target Price14.84 Perf Year-39.44%
Cash/sh2.27 P/C3.34 EPS next 5Y40.00% ROE-58.90% 52W Range5.96 - 12.99 Perf YTD-30.59%
Dividend- P/FCF- EPS past 5Y-7.30% ROI-56.20% 52W High-40.44% Beta0.42
Dividend %- Quick Ratio8.90 Sales past 5Y- Gross Margin85.30% 52W Low29.87% ATR0.34
Employees151 Current Ratio9.30 Sales Q/Q83.30% Oper. Margin- RSI (14)53.26 Volatility2.65% 4.31%
OptionableYes Debt/Eq0.20 EPS Q/Q-1.20% Profit Margin- Rel Volume1.57 Prev Close7.60
ShortableYes LT Debt/Eq0.20 EarningsNov 12 AMC Payout- Avg Volume109.42K Price7.74
Recom1.70 SMA20-1.17% SMA501.36% SMA200-4.59% Volume172,105 Change1.84%
Nov-13-19Reiterated H.C. Wainwright Buy $17.50 → $16
Jul-16-19Downgrade B. Riley FBR Buy → Neutral $18 → $8.50
Jun-11-19Initiated Barclays Overweight $13
May-23-19Initiated Stifel Buy
May-23-19Initiated Guggenheim Buy $11
Mar-07-19Reiterated Lake Street Buy $30 → $12
Nov-08-18Reiterated B. Riley FBR Buy $16 → $21
Jul-24-18Initiated Cantor Fitzgerald Overweight
Dec-27-17Initiated CL King Neutral
Nov-20-17Resumed B. Riley FBR, Inc. Buy $11
Nov-17-17Initiated H.C. Wainwright Buy $9.50
May-24-17Initiated FBR & Co. Outperform $10
Nov-01-16Initiated Ladenburg Thalmann Buy $7.50
Jan-24-14Downgrade BMO Capital Markets Outperform → Market Perform $15
Dec-06-19 10:36AM  Should You Worry About Kindred Biosciences, Inc.'s (NASDAQ:KIN) CEO Pay Cheque? Simply Wall St.
Nov-28-19 02:29PM  Edited Transcript of KIN earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-25-19 04:03PM  Kindred Biosciences Receives FDA Approval of Zimeta (dipyrone injection) for the Control of Pyrexia in Horses PR Newswire
Nov-14-19 04:05PM  Kindred Biosciences to Participate in Stifel Healthcare Conference and Jefferies London Healthcare Conference PR Newswire
Nov-12-19 05:45PM  Kindred Biosciences (KIN) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:01PM  Kindred Biosciences Announces Third Quarter 2019 Financial Results PR Newswire
Nov-05-19 10:33AM  Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-28-19 08:31AM  Kindred Biosciences to Announce Third Quarter 2019 Financial Results PR Newswire
Oct-18-19 10:23AM  These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals +6.83%
Oct-10-19 04:02PM  Kindred Biosciences Announces Positive Opinion from CVMP in the European Union for Mirataz® (mirtazapine transdermal ointment) for Cats Experiencing Poor Appetite and Weight Loss PR Newswire
Oct-07-19 03:27PM  Is Kindred Biosciences (NASDAQ:KIN) In A Good Position To Invest In Growth? Simply Wall St.
Oct-02-19 07:01AM  Kindred Biosciences Secures $50 Million Debt Facility with Solar Capital Partners PR Newswire
Sep-27-19 02:54AM  Unibet Takes on its Second U.S. Market PR Newswire
Sep-10-19 07:01AM  Kindred Biosciences Awarded a Contract by the National Cancer Institute in Support of the PREVENT Cancer Program PR Newswire
Aug-28-19 08:31AM  Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Lake Street Best Ideas Growth Conference, and Cantor Global Healthcare Conference PR Newswire
Aug-07-19 10:51AM  The Kindred Biosciences (NASDAQ:KIN) Share Price Has Gained 88% And Shareholders Are Hoping For More Simply Wall St.
03:33AM  Edited Transcript of KIN earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-02-19 10:24AM  Kindred Biosciences (KIN) Q2 2019 Earnings Call Transcript Motley Fool +10.20%
Aug-01-19 06:45PM  Kindred Biosciences (KIN) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM  Kindred Biosciences Announces Second Quarter 2019 Financial Results and Unveils Positive Results from Pilot Efficacy Study of Parvovirus Monoclonal Antibody PR Newswire
Jul-29-19 07:01AM  Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs PR Newswire
Jul-16-19 08:31AM  Kindred Biosciences to Announce Second Quarter 2019 Financial Results PR Newswire -11.76%
Jun-28-19 06:40PM  Heres What Hedge Funds Think About Kindred Biosciences Inc (KIN) Insider Monkey
Jun-21-19 09:47AM  A Handful of Small Biotechs That Make for Merger Chatter TheStreet.com
May-13-19 08:31AM  Kindred Biosciences to Participate in the B. Riley FBR Institutional Investor Conference, Stifel 2019 Dental & Veterinary Conference and 9th Annual LD Micro Invitational PR Newswire
May-10-19 01:24PM  Kindred Biosciences (KIN) Q1 2019 Earnings Call Transcript Motley Fool
01:50AM  Edited Transcript of KIN earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-09-19 06:15PM  Kindred Biosciences (KIN) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:07PM  Kindred Bio: 1Q Earnings Snapshot Associated Press
04:01PM  Kindred Biosciences Announces First Quarter 2019 Financial Results PR Newswire
May-07-19 11:54AM  Do Institutions Own Kindred Biosciences, Inc. (NASDAQ:KIN) Shares? Simply Wall St.
Apr-25-19 08:01AM  Kindred Biosciences to Announce First Quarter 2019 Financial Results PR Newswire +5.90%
Mar-13-19 02:03AM  Edited Transcript of KIN earnings conference call or presentation 6-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-07-19 01:19PM  Kindred Biosciences, Inc. (NASDAQ:KIN) Has Attractive Fundamentals Simply Wall St. -10.88%
Mar-06-19 09:21PM  Kindred Biosciences Inc (KIN) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Feb-19-19 08:31AM  Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results PR Newswire
Feb-13-19 08:31AM  Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference PR Newswire
02:03AM  Kindred Group plc - Year end report January - December 2018 (Unaudited) PR Newswire
Jan-25-19 02:02PM  Bringing world class medication to animals Yahoo Finance Video
Jan-23-19 04:10PM  Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jan-22-19 08:31AM  Kindred Biosciences Named Best Company in North America by Leading Industry Publication PR Newswire
Jan-18-19 09:31AM  Kindred Biosciences Announces Pricing of Public Offering PR Newswire -8.03%
Jan-17-19 04:01PM  Kindred Biosciences Announces Proposed Public Offering of Common Stock PR Newswire
Jan-14-19 07:01AM  Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital PR Newswire
Nov-16-18 08:35AM  Recent Analysis Shows Spirit Airlines, Cactus, Evergy, ADDvantage Technologies Group, Kindred Biosciences, and Farfetch Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-14-18 01:36AM  Edited Transcript of KIN earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-18 04:01PM  Kindred Biosciences Announces Third Quarter 2018 Financial Results PR Newswire
Oct-30-18 04:01PM  Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent PR Newswire
Oct-24-18 08:31AM  Kindred Biosciences to Announce Third Quarter 2018 Financial Results PR Newswire -6.24%
Oct-23-18 07:31AM  Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President PR Newswire
Sep-17-18 08:31AM  Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference PR Newswire
Aug-30-18 08:31AM  Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit PR Newswire
Aug-26-18 11:55PM  Edited Transcript of KIN earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-21-18 08:31AM  Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference PR Newswire
Aug-09-18 04:01PM  Kindred Biosciences Announces Second Quarter 2018 Financial Results PR Newswire
Jul-16-18 08:31AM  Kindred Biosciences to Announce Second Quarter 2018 Financial Results PR Newswire
Jul-09-18 08:31AM  Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States PR Newswire
Jun-26-18 05:55PM  [$$] Kindred Biosciences' Top Holder Buys $8M More in Stock Barrons.com
Jun-25-18 09:01AM  Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock PR Newswire
Jun-20-18 04:01PM  Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program PR Newswire
09:10AM  Kindred Biosciences Announces Pricing of Public Offering PR Newswire
Jun-19-18 04:01PM  Kindred Biosciences Announces Proposed Public Offering of Common Stock PR Newswire
May-31-18 06:46AM  Who Owns Most Of Prima Park SA. (WSE:KIN)? Simply Wall St.
May-30-18 07:02AM  KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses PR Newswire
May-29-18 08:02AM  Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational Conference PR Newswire
May-24-18 07:02AM  Kindred Biosciences to Present at Stifel 2018 Dental & Veterinary Conference PR Newswire
May-14-18 01:41AM  Edited Transcript of KIN earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 09:10AM  Unlocking The Value In Animal Medicine Forbes
May-09-18 07:05AM  Blog Exposure - Kindred Biosciences Gets FDA Approval for Mirataz ACCESSWIRE
May-08-18 04:01PM  Kindred Biosciences Announces First Quarter 2018 Financial Results PR Newswire
10:15AM  Is Prima Park SA. (WSE:KIN) A Financially Sound Company? Simply Wall St.
May-07-18 04:43PM  This Peninsula company's new drug is the cat's meow the FDA says so American City Business Journals
09:11AM  Weight Gain Season for Felines The Wall Street Journal
07:00AM  Kindred Biosciences Receives FDA Approval of Mirataz (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats PR Newswire
Apr-25-18 04:02PM  Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors PR Newswire
Apr-24-18 04:02PM  Kindred Biosciences Provides Updates on Pending Drug Approvals PR Newswire
Apr-18-18 04:01PM  Kindred Biosciences to Announce First Quarter 2018 Financial Results PR Newswire
Mar-08-18 04:01PM  Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference PR Newswire
Mar-02-18 02:16PM  Edited Transcript of KIN earnings conference call or presentation 1-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-18 04:01PM  Kindred Biosciences Announces Fourth Quarter and Full Year 2017 Financial Results PR Newswire
12:30PM  Kindred Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-18 08:30AM  Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results PR Newswire
Feb-13-18 08:30AM  Kindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health Summit PR Newswire
Dec-21-17 08:02AM  KindredBio Announces Submission of European Medicines Agency Filing for Mirataz PR Newswire
Dec-04-17 08:02AM  KindredBio Announces Positive Results from Pivotal Study of Zimeta Oral for Fever in Horses PR Newswire
Nov-19-17 08:51PM  Edited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-17 05:27PM  Kindred Bio reports 3Q loss Associated Press
04:01PM  Kindred Biosciences Announces Third Quarter 2017 Financial Results PR Newswire
10:40AM  Kindred Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Oct-11-17 09:01AM  Kindred Biosciences to Announce Third Quarter 2017 Financial Results PR Newswire
Oct-05-17 04:01PM  Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference PR Newswire
Sep-11-17 09:00AM  Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof PR Newswire
Aug-30-17 09:02AM  Kindred Biosciences to Present at Upcoming Investor Conferences PR Newswire
Aug-12-17 05:40AM  Edited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-17 11:58PM  Kindred Bio reports 2Q loss Associated Press
04:01PM  Kindred Biosciences Announces Second Quarter 2017 Financial Results PR Newswire
06:40AM  Investor Network: Kindred Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Aug-04-17 09:02AM  Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting PR Newswire
Aug-01-17 08:34AM  Liolios 6th Annual Gateway Conference to Showcase 100 Companies at the Four Seasons San Francisco on September 6-7 GlobeNewswire
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-014 to treat gastric ulcers in horses; epoCat, a feline recombinant erythropoietin for the management of anemia in cats; KIND-011, a monoclonal antibody that targets sick or septic foals; and KIND-509, an antibody for canine inflammatory bowel disease. Further, it is developing KIND-015 for the management of clinical signs associated with equine metabolic syndrome and anti-tumor necrosis factor in septic foals; KIND-502, an IgE antibody that targets the canine counterpart of the human target for allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; and various antibodies that target cytokines involved in atopic dermatitis, as well as interleukin antibodies and canine checkpoint inhibitors. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Park West Asset Management LLC10% OwnerJan 18Buy9.50741,8407,047,4806,743,893Jan 23 04:23 PM
Chin RichardChief Executive OfficerJan 02Sale10.5740,000422,7161,906,071Jan 04 08:41 PM